After conducting a meta-analysis of the supporting preclinical application materials submitted to institutional review boards (IRBs) for more than 100 clinical trials, researchers at the German Hannover Medical School found that those application materials were deficient in the vast majority of applications, to the point that "poor [preclinical efficacy studies] design and reporting thwart risk/benefit evaluation during ethical review of phase I/II studies."